Patient Perspectives on Performance of a Smartphone App for Atrial FibrillationSelf-Management

Patient Perspectives on Conversational Artificial Intelligence for Atrial Fibrillation Self-Management: Qualitative Analysis

BACKGROUND

Conversational artificial intelligence (AI) allows for engaging interactions, however, its acceptability, barriers, and enablers to support patients with atrial fibrillation (AF) are unknown.

OBJECTIVE

This work stems from the Coordinating Health care with AI-supported Technology for patients with AF (CHAT-AF) trial and aims to explore patient perspectives on receiving support from a conversational AI support program.

METHODS

Patients with AF recruited for a randomized controlled trial who received the intervention were approached for semistructured interviews using purposive sampling. The 6-month intervention consisted of fully automated conversational AI phone calls (with speech recognition and natural language processing) that assessed patient health and provided self-management support and education. Interviews were recorded, transcribed, and thematically analyzed.

RESULTS

We conducted 30 interviews (mean age 65.4, SD 11.9 years; 21/30, 70% male). Four themes were identified: (1) interaction with a voice-based conversational AI program (human-like interactions, restriction to prespecified responses, trustworthiness of hospital-delivered conversational AI); (2) engagement is influenced by the personalization of content, delivery mode, and frequency (tailoring to own health context, interest in novel information regarding health, overwhelmed with large volumes of information, flexibility provided by multichannel delivery); (3) improving access to AF care and information (continuity in support, enhancing access to health-related information); (4) empowering patients to better self-manage their AF (encouraging healthy habits through frequent reminders, reassurance from rhythm-monitoring devices).

CONCLUSIONS

Although conversational AI was described as an engaging way to receive education and self-management support, improvements such as enhanced dialogue flexibility to allow for more naturally flowing conversations and tailoring to patient health context were also mentioned.

TRIAL REGISTRATION

Australian New Zealand Clinical Trials Registry ACTRN12621000174886; https://tinyurl.com/3nn7tk72.

INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)

RR2-10.2196/34470.

Promises and Perils of Consumer Mobile Technologies in Cardiovascular Care: JACC Scientific Statement

Direct-to-consumer (D2C) wearables are becoming increasingly popular in cardiovascular health management because of their affordability and capability to capture diverse health data. Wearables may enable continuous health care provider-patient partnerships and reduce the volume of episodic clinic-based care (thereby reducing health care costs). However, challenges arise from the unregulated use of these devices, including questionable data reliability, potential misinterpretation of information, unintended psychological impacts, and an influx of clinically nonactionable data that may overburden the health care system. Further, these technologies could exacerbate, rather than mitigate, health disparities. Experience with wearables in atrial fibrillation underscores these challenges. The prevalent use of D2C wearables necessitates a collaborative approach among stakeholders to ensure effective integration into cardiovascular care. Wearables are heralding innovative disease screening, diagnosis, and management paradigms, expanding therapeutic avenues, and anchoring personalized medicine.

Engagement of atrial fibrillation patients with the AF-EduApp, a new mobile application to support AF management

Introduction

A multidisciplinary approach is needed for the management of atrial fibrillation (AF) in which the patient has a central role. Smart devices create opportunities to improve AF management. This paper aimed to evaluate the in-house developed AF-EduApp application on its usability, satisfaction, and communication effectiveness with the care team.

Methods

During a multicenter, prospective randomized controlled trial, 153 AF patients were included in the AF-EduApp study, with a minimum follow-up of 12 months and a maximum follow-up of 15 months if taking oral anticoagulation (OAC). The AF-EduApp contains six main modules: Questionnaires, Education, Measurement data entry, Medication overview with reminders, Appointments, and Communication with the care team. The App focuses on four main goals: (1) to improve AF knowledge, (2) to increase self-care capabilities, (3) electronic monitoring to improve therapy adherence to OAC, and (4) communication with the care team. Patients unable to use the AF-EduApp were assigned to a no-App control group (n = 41) without intervention comparable to the standard care group (SC, n = 346) of the AF-EduCare study.

Results

A total of 152 patients effectively used the App during a mean follow-up of 386.8 ± 108. 1 days (one included patient could not install the application due to an iPhone from the United States). They opened the application on average on 130.1 ± 144.7 days. Of the 109 patients still in follow-up after 12 months (i.e. patients who did not withdraw and on OAC), 90 patients (82.6%) actively used the application at least one day in the next 41 days. The Measurement module was the most used, with a median of used days over the total available days of 6.4%. A total of 75 App patients (49.3%) asked questions, mostly clinical-related questions (e.g. medication use, or actionability on clinical entered parameters). A mean score of 8.1 ± 1.7 about the "perceived quality of follow-up in the past year" was given by the App ITT patients, compared to a score of 7.7 ± 2.0 by the SC group (P = .072). Patients who used the App were more attracted to future follow-up with an application compared to patients who would be capable of using the application of the SC group (31.6% vs. 12.5%; P < .001).

Conclusion

This study showed a positive attitude towards using a mobile application, with AF patients using the application one-third of the available days. Patients used the App most for entering measured parameters, and to contact the care team.